Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Dia, Ndongo ^a   Niang, Mbayame N ^a   Diadhiou, Saadiya A ^b   Goudiaby, Déborah G ^a   Faye, Abdourahmane ^a   Kiori, Davy ^a   Bâ, Mady ^b   Michel, Rémy ^a   Diop, Ousmane M ^a  

^a INSTITUT PASTEUR DE DAKAR   (Senegal)

^b Division SIDA IST   (Senegal)

Author keywords

Influenza; Oseltamivir; Resistance

Indexed keywords

ADAMANTANE; OSELTAMIVIR; PROTEIN M2; SIALIDASE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; HA GENE; IC 50; INFLUENZA A (H1N1); M2 GENE; MUTATIONAL ANALYSIS; NEUROAMINIDASE GENE; NONHUMAN; PHENOTYPIC VARIATION; PHYLOGENETIC TREE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS ISOLATION; VIRUS STRAIN;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OSELTAMIVIR; PHYLOGENY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENEGAL;

EID: 84874234135     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-106     Document Type: Article

References (26)

1. Woods JM, Bethell RC, Coates JAV, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcot SMAND, Penn CR. 4-Guanidino-2, 4-dideoxy-2, 3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (NA) and of growth of a wide range of infuenza A and B viruses in vitro. Antimicrob Agents Chemother 1993, 37:1473-1479. 10.1128/AAC.37.7.1473, 187997, 8363379.
2. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997, 119:681-690. 10.1021/ja963036t, 16526129.
3. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001, 20:127-133. 10.1097/00006454-200102000-00002, 11224828.
4. Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res 2004, 103:195-197. 10.1016/j.virusres.2004.02.033, 15163509.
5. Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci 2001 Dec 29, 356(1416):1895-1897.
6. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002 Aug, 55(2):307-317.
7. ECDC Timeline for the emergence of oseltamivir resistant influenza A(H1N1) 2007-8 [cited 2008 November 21] Available from http://ecdc.europa.eu/en/healthtopics/documents/0810_seasonal_influenza_avr_timeline.pdf, ECDC.
8. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009, 15:155-162. 10.3201/eid1502.081031, 2657637, 19193257.
9. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Eur Surveill 2008, 13:ii 8026.
10. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, Opp M, Paget J, van-de-Kassteel J, Hay A, Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 Season. Emerg Infect Dis 2009, 15:552-560. 10.3201/eid1504.081280, 2671453, 19331731.
11. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei IP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D'Souza H, Komadina N, Shaw R, Kelso A, Barr I. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009, 83:90-93. 10.1016/j.antiviral.2009.03.003, 19501261.
12. Besselaar TG, Naidoo D, Buys A, Gregory V, McAnerney J, Manamela JM, Blumberg L, Schoub BD. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa [letter]. Emerg Infect Dis 2008, 14(11):1809-1810. 10.3201/eid1411.080958, 2630761, 18976580.
13. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993, 67:5585-5594. 237962, 7688826.
14. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenzaAviruses to amantadine. J Antimicrob Chemother 1986, 18(suppl B):19-29.
15. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988, 62:1508-1512. 253174, 3282079.
16. Dosseh A, Ndiaye K, Spiegel A, Sagna M, Mathiot C. Epidemiological and virological influenza survey in Dakar, Senegal: 1996-1998. Am J Trop Med Hyg 2000, 62:639-643.
17. World Health Organization WHO Manual on Animal influenza Diagnosis and Surveillance 2002, Geneva: World Health Organization, World Health Organization.
18. Guo L, Garten RJ, Foust AS, Sessions WM, Okomo-Adhiambo M, Gubareva LV, Klimov AI, Xu X. Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antiviral Res 2009, 82:1. 10.1016/j.antiviral.2008.12.015, 19187793.
19. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance and maximum parsimony methods. Mol Biol Evol 2011, 28:2731-2739. 10.1093/molbev/msr121, 3203626, 21546353.
20. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp 1999, 41:95-98.
21. Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob. Agents Chemother. 49, 556-559. Antiviral Res 2005, 82(1):29-33.
22. Niang MN, Dosseh A, NDiaye K, Sagna M, Victoria Gregory V, Deborah G, Alan Hay A, Diop OM. Sentinel surveillance for influenza in Senegal, 1996-2009 49122, In press JID supplement (manuscript number: 49122).
23. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007, 12:603-616.
24. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765. 10.1016/S0140-6736(04)16934-1, 15337401.
25. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005, 55(Suppl 1):i5-i21.
26. Neuraminidase Inhibitor Susceptibility Network Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec 2005, 80:156. Neuraminidase Inhibitor Susceptibility Network.